In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species

George Richard Thompson, Nathan P. Wiederhold, Deanna A. Sutton, Annette Fothergill, Thomas F. Patterson

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Objectives: The emergence of less common, but clinically important, fungal pathogens including the rare yeasts has contributed to the substantial morbidity and mortality observed in immunocompromised patients. These organisms can be resistant or refractory to existing antifungal agents. We sought to evaluate the activity of the new triazole isavuconazole against these difficult pathogens. Methods: MICs of isavuconazole, voriconazole, posaconazole, fluconazole, amphotericin B and flucytosine were determined for 54 Trichosporon, 7 Geotrichum capitatum, 18 Saccharomyces cerevisiae, 11 Pichia and 14 Rhodotorula species in accordance with the M27-A2 reference method. Minimum fungicidal concentrations were also measured for each agent. Results: Isavuconazole demonstrated excellent in vitro activity against each species tested. MIC90 values ranged between 0.125 and 0.25 mg/L against Trichosporon isolates, and between 0.03 and 0.5 mg/L against the other yeast tested. The geometric mean MICs of isavuconazole were similar to those of voriconazole and similar or less than those of posaconazole, fluconazole, amphotericin B and flucytosine for all species tested. This activity was also maintained against one Trichosporon asahii and nine Rhodotorula isolates that were resistant to fluconazole. Conclusions: Isavuconazole is a welcome addition to the growing antifungal armamentarium with potent in vitro activity against emerging yeast pathogens. Although this agent may be useful in the treatment of the rare yeasts, clinical data are needed to verify these results.

Original languageEnglish (US)
Pages (from-to)79-83
Number of pages5
JournalJournal of Antimicrobial Chemotherapy
Volume64
Issue number1
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Geotrichum
Trichosporon
Rhodotorula
Saccharomyces
Pichia
Fluconazole
Yeasts
Flucytosine
Amphotericin B
Triazoles
Antifungal Agents
Immunocompromised Host
varespladib methyl
Saccharomyces cerevisiae
In Vitro Techniques
isavuconazole
Morbidity
Mortality

Keywords

  • Blastoschizomyces capitatum
  • MICs
  • Rare yeasts
  • Triazoles

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. / Thompson, George Richard; Wiederhold, Nathan P.; Sutton, Deanna A.; Fothergill, Annette; Patterson, Thomas F.

In: Journal of Antimicrobial Chemotherapy, Vol. 64, No. 1, 2009, p. 79-83.

Research output: Contribution to journalArticle

Thompson, George Richard ; Wiederhold, Nathan P. ; Sutton, Deanna A. ; Fothergill, Annette ; Patterson, Thomas F. / In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. In: Journal of Antimicrobial Chemotherapy. 2009 ; Vol. 64, No. 1. pp. 79-83.
@article{15ed1c211f10484b9049a144265600f9,
title = "In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species",
abstract = "Objectives: The emergence of less common, but clinically important, fungal pathogens including the rare yeasts has contributed to the substantial morbidity and mortality observed in immunocompromised patients. These organisms can be resistant or refractory to existing antifungal agents. We sought to evaluate the activity of the new triazole isavuconazole against these difficult pathogens. Methods: MICs of isavuconazole, voriconazole, posaconazole, fluconazole, amphotericin B and flucytosine were determined for 54 Trichosporon, 7 Geotrichum capitatum, 18 Saccharomyces cerevisiae, 11 Pichia and 14 Rhodotorula species in accordance with the M27-A2 reference method. Minimum fungicidal concentrations were also measured for each agent. Results: Isavuconazole demonstrated excellent in vitro activity against each species tested. MIC90 values ranged between 0.125 and 0.25 mg/L against Trichosporon isolates, and between 0.03 and 0.5 mg/L against the other yeast tested. The geometric mean MICs of isavuconazole were similar to those of voriconazole and similar or less than those of posaconazole, fluconazole, amphotericin B and flucytosine for all species tested. This activity was also maintained against one Trichosporon asahii and nine Rhodotorula isolates that were resistant to fluconazole. Conclusions: Isavuconazole is a welcome addition to the growing antifungal armamentarium with potent in vitro activity against emerging yeast pathogens. Although this agent may be useful in the treatment of the rare yeasts, clinical data are needed to verify these results.",
keywords = "Blastoschizomyces capitatum, MICs, Rare yeasts, Triazoles",
author = "Thompson, {George Richard} and Wiederhold, {Nathan P.} and Sutton, {Deanna A.} and Annette Fothergill and Patterson, {Thomas F.}",
year = "2009",
doi = "10.1093/jac/dkp138",
language = "English (US)",
volume = "64",
pages = "79--83",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species

AU - Thompson, George Richard

AU - Wiederhold, Nathan P.

AU - Sutton, Deanna A.

AU - Fothergill, Annette

AU - Patterson, Thomas F.

PY - 2009

Y1 - 2009

N2 - Objectives: The emergence of less common, but clinically important, fungal pathogens including the rare yeasts has contributed to the substantial morbidity and mortality observed in immunocompromised patients. These organisms can be resistant or refractory to existing antifungal agents. We sought to evaluate the activity of the new triazole isavuconazole against these difficult pathogens. Methods: MICs of isavuconazole, voriconazole, posaconazole, fluconazole, amphotericin B and flucytosine were determined for 54 Trichosporon, 7 Geotrichum capitatum, 18 Saccharomyces cerevisiae, 11 Pichia and 14 Rhodotorula species in accordance with the M27-A2 reference method. Minimum fungicidal concentrations were also measured for each agent. Results: Isavuconazole demonstrated excellent in vitro activity against each species tested. MIC90 values ranged between 0.125 and 0.25 mg/L against Trichosporon isolates, and between 0.03 and 0.5 mg/L against the other yeast tested. The geometric mean MICs of isavuconazole were similar to those of voriconazole and similar or less than those of posaconazole, fluconazole, amphotericin B and flucytosine for all species tested. This activity was also maintained against one Trichosporon asahii and nine Rhodotorula isolates that were resistant to fluconazole. Conclusions: Isavuconazole is a welcome addition to the growing antifungal armamentarium with potent in vitro activity against emerging yeast pathogens. Although this agent may be useful in the treatment of the rare yeasts, clinical data are needed to verify these results.

AB - Objectives: The emergence of less common, but clinically important, fungal pathogens including the rare yeasts has contributed to the substantial morbidity and mortality observed in immunocompromised patients. These organisms can be resistant or refractory to existing antifungal agents. We sought to evaluate the activity of the new triazole isavuconazole against these difficult pathogens. Methods: MICs of isavuconazole, voriconazole, posaconazole, fluconazole, amphotericin B and flucytosine were determined for 54 Trichosporon, 7 Geotrichum capitatum, 18 Saccharomyces cerevisiae, 11 Pichia and 14 Rhodotorula species in accordance with the M27-A2 reference method. Minimum fungicidal concentrations were also measured for each agent. Results: Isavuconazole demonstrated excellent in vitro activity against each species tested. MIC90 values ranged between 0.125 and 0.25 mg/L against Trichosporon isolates, and between 0.03 and 0.5 mg/L against the other yeast tested. The geometric mean MICs of isavuconazole were similar to those of voriconazole and similar or less than those of posaconazole, fluconazole, amphotericin B and flucytosine for all species tested. This activity was also maintained against one Trichosporon asahii and nine Rhodotorula isolates that were resistant to fluconazole. Conclusions: Isavuconazole is a welcome addition to the growing antifungal armamentarium with potent in vitro activity against emerging yeast pathogens. Although this agent may be useful in the treatment of the rare yeasts, clinical data are needed to verify these results.

KW - Blastoschizomyces capitatum

KW - MICs

KW - Rare yeasts

KW - Triazoles

UR - http://www.scopus.com/inward/record.url?scp=67249103186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67249103186&partnerID=8YFLogxK

U2 - 10.1093/jac/dkp138

DO - 10.1093/jac/dkp138

M3 - Article

VL - 64

SP - 79

EP - 83

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 1

ER -